GGrantIndex
← Leaderboards

Zymeron Corporation

Durham, NC

Compare ↔
$8,334,982
Total funding
20
Grants

Funding over time

peak $3M · FY201723
$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,134,982 · 19
DOE$200,000 · 1

By mechanism

N43$3,936,111 · 14
N44$3,000,000 · 2
N01$1,198,871 · 3
$200,000 · 1

Investigators at Zymeron Corporation

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

Not enough data

Largest grants

RAPID POINT OF CARE TESTS FOR TUBERCULOSIS$1,500,000
N44 · FY2021 · AI
Rapid Point of Care Diagnostics to Determine Cytomegalovirus Infection Serostatus$1,500,000
N44 · FY2019 · AI
Synthetic Affinity Resins for One Step Purification of HIV Envelope Protein$599,061
N01 · FY2018 · AI
One Test, One Kit for Identifying Active Hepatitis C Virus (HCV) Infection at Home$400,000
N43 · FY2022 · CA
DEVELOPMENT OF PEDIATRIC TUBERCULOSIS TREATMENT$300,000
N43 · FY2021 · AI
ANTIVIRAL DRUG DEVELOPMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION$300,000
N43 · FY2020 · AI
Small Molecule Degraders of Intracellular HIV Proteins as Novel Anti-HIV Therapeutics$300,000
N43 · FY2021 · AI
Adjuvanted Virus-Mimicking Nanoparticle HIV Vaccine$300,000
N43 · FY2021 · AI
POINT-OF-CARE (POC) DIAGNOSTICS FOR ANTIMICROBIAL RESISTANT PATHOGENS$300,000
N01 · FY2022 · AI
RAPID POINT OF CARE TESTS FOR HEPATITIS C VIRUS$300,000
N43 · FY2021 · AI
Novel Nanoparticle-in-Hydrogel Co-delivery of Adjuvanted saRNA as HIV Vaccine$300,000
N43 · FY2020 · AI
SBIR Phase 1 - Topic 394 - Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics.$299,998
N43 · FY2019 · CA
RAPID POINT OF CARE DIAGNOSTIC TEST FOR HISTOPLASMOSIS$299,998
N43 · FY2020 · AI
Rapid Point of Care Test to Quantify HIV Drugs for Adherence Monitoring$299,988
N43 · FY2021 · AI
RAPID POINT OF CARE TESTS FOR TUBERCULOSIS$299,920
N43 · FY2019 · AI
Topic 374 - Phase I - Targeted and Sustained Release Microparticles for Colon CancerChemoprevention$299,810
N01 · FY2018 · CA
In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents$299,794
N43 · FY2019 · AI
Rapid point of Care Diagnostics to Determine Cytomegalovirus Infection$222,693
N43 · FY2017 · AI
ADVANCED PORTABLE LOW TEMPERATURE PLASMA DEVICE FOR CHRONIC WOUND DISINFECTION AND HEALING$200,000
· FY2023 · Department of Energy
Rapid Point of Care Test to Screen Human Papillomavirus in Low-Resource Settings$13,720
N43 · FY2023 · CA